Login / Signup

Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.

Josephine A HinnehJoanna L GillisChui Yan MahSwati IraniRaj K ShresthaNatalie K RyanAtsushi EnomotoZeyad D NassarDavid John LynnLuke A SelthMasashi KatoMargaret M CenteneraLisa M Butler
Published in: British journal of cancer (2023)
Co-targeting HMMR and AR represents an effective strategy for improving response to ARSIs.
Keyphrases
  • prostate cancer
  • cancer therapy
  • radical prostatectomy
  • biofilm formation
  • drug delivery
  • escherichia coli
  • pseudomonas aeruginosa
  • binding protein
  • cystic fibrosis